VRDN Viridian Therapeutics, Inc. Common Stock
XNAS
29.89
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VRDN
$29.89
—
What changed
Recent filings, trades and movesKey stats
$29.89
- 52-Week Range
- $13.18 – $34.29
- YTD
- -2.56%
- IV Rank (30D)
- 13.4
- Straddle Price
- $4.95
- P/C Vol Ratio
- 0.45
- Market Cap
- $3.2B
- Open
- $29.29
- Day Range
- $28.60 – $30.38
- Volume
- 2,213,055
- Prev Close
- $28.49
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.86 |
| Cost of Equity (CAPM) | 9.20% (VRP-adj) |
| WACC | 8.84% |
| Volatility Risk Premium | +35.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -68.4% |
| Book / Price | 17.9% |
| Gross Margin (TTM) | 94.2% |
| FCF Margin (TTM) | -1273.5% |
| Debt / Equity | 0.63 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $21.97 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $23.13 |
| Bollinger Width / SMA20 | 56.8% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $3B |
Peers used for multiples: BLLN, COGT, CORT, DNTH, GH, MIRM, SYRE, TVTX
60-Day Conviction
70%
20-Day Fair Value
≈ by Dec 8, 2026
$29.24
α -2.1%
rank 18%
conviction
93%
40-Day Fair Value
≈ by Jan 6, 2027
$29.35
α -1.7%
rank 18%
conviction
58%
60-Day Fair Value
≈ by Feb 4, 2027
$28.93
α -3.1%
rank 18%
conviction
70%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $48.39 | 11% | median 9.5× · 6 peers |
| Peer P/S | $2.88 | 11% | median 11.3× · 6 peers |
| Market Anchor (SMA50) | $21.97 | 49% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $28.31 | 29% | 22 strikes · skew +0.30 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.2B
- Employees
- 252
- List Date
- 2014-06-18
- CIK
- 0001590750
- Last Earnings
- Nov 4 before open · +15.5% vs ±19.7% expected
- Headquarters
- Waltham, MA
- Homepage
- https://www.viridiantherapeutics.com
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -18.33% | -3.13% | 28.14% | -13.87% | -1.92% | 7.56% | -0.26% |
| Feb | -8.05% | -7.33% | -12.17% | -6.45% | -19.53% | -11.51% | -10.84% |
| Mar | -1.71% | 4.82% | -23.05% | -11.97% | -6.45% | -35.34% | -12.28% |
| Apr | 15.73% | -26.34% | 10.22% | -23.17% | 7.88% | -29.61% | -7.55% |
| May | 0.17% | -5.57% | -16.79% | -13.47% | 1.31% | 31.30% | -0.51% |
| Jun | 4.81% | -4.70% | -2.90% | 8.42% | 0.07% | 8.31% | 2.33% |
| Jul | -13.27% | 23.74% | -24.05% | 27.55% | 21.08% | 0.05% | 5.85% |
| Aug | -10.92% | 63.55% | -2.57% | -9.83% | 5.57% | 19.94% | 10.96% |
| Sep | 24.91% | -3.30% | -19.73% | 57.22% | 12.75% | -10.59% | 10.21% |
| Oct | 9.56% | -4.19% | -14.38% | -8.64% | 11.10% | 29.91% | 3.89% |
| Nov | 6.12% | 27.88% | 32.86% | -3.28% | 38.06% | 17.96%* | 19.93% |
| Dec | 7.21% | 12.17% | 26.48% | -8.71% | -1.05% | -- | 7.22% |
| Total | 7.88% | 67.76% | -34.09% | -25.43% | 76.64% | 1.29% | 15.68% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $23.71
SMA 50: $22.11
SMA 200: $21.61
Current: $29.83
EMA 12: $26.22
EMA 26: $24.08
MACD: 2.1345 | Signal: 0.7072
BULLISH
ADX (14): 45.86
STRONG TREND
+DI: 42.13
−DI: 9.10
Momentum Oscillators
RSI (14): 79.90
OVERBOUGHT
Stoch %K: 89.43
Stoch %D: 89.49
Williams %R: -6.50
Volume & Volatility
BB Upper: $30.50
BB Lower: $16.92
NEUTRAL
OBV: 2,202,490
Vol SMA 20: 2,891,747
Vol ROC: 45.47%
ATR: $1.37
True Range: $1.89
HV 20: 67.9%
HV 30: 68.3%
HV 60: 56.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before VRDN’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (6/10) with a bullish bias due to recent price action and momentum signals.
Key Drivers:
- Bullish MACD crossover
- Strong ADX reading indicating a strong trend regime
- Above-average institutional interest
Primary Risks:
- Overbought RSI reading
- Negative news sentiment from recent headlines
- High volatility compared to the broader market
Investment Thesis: VRDN has been trending upward due to recent positive news and momentum signals. While it is overbought in the short term, its strong trend regime and bullish MACD crossover suggest it may be poised for a continued uptrend.
Recent News Sentiment Impact: The recent negative headlines from The Motley Fool and GlobeNewswire Inc. have had a neutral impact on sentiment, as they are not particularly surprising given the company's recent volatility. However, the positive headline from Benzinger Inc. has contributed to the overall bullish bias.
Technical Analysis
Trend Direction:
- Short-term: Uptrend (1-4 weeks)
- Medium-term: Uptrend (1-3 months)
- Long-term: Uptrend (3-12 months)
Support/Resistance Levels:
- Upper Bollinger Band: $25.75
- Middle Bollinger Band: $23.02
- Lower Bollinger Band: $20.29
Momentum Signals: RSI Interpretation: Overbought (>70), suggesting a potential pullback or consolidation.
MACD Signal: Bullish crossover, indicating an uptrend.
Bollinger Bands Position: Neutral, with the price within the middle band.
Volume Analysis: Volume SMA 20: 1676149.01 On-Balance Volume (OBV): 25704618.62 Volume Rate of Change: -28.72%
News & Sentiment Analysis
Recent Headlines Summary:
- The Motley Fool's article on June 30 FDA catalyst and Kopp Family Office trimming their stake by $7 million.
- J.Jill, Inc. shareholders being encouraged to reach out to Johnson Fistel for potentially recovering losses.
Sentiment Assessment: Neutral sentiment with a slight lean towards negativity due to recent news headlines.
Catalyst Identification:
- Upcoming FDA decision on June 30
- Potential earnings beat or miss in the near term
Market Narrative: The market is currently pricing in a potential move of $4.88 by expiration, which could be driven by the upcoming FDA decision and earnings release.
Risk & Volatility Assessment
Beta Interpretation: Above average volatility (1.05 vs SPY), indicating a higher risk profile compared to the broader market.
Volatility Regime: Current volatility is above its historical mean, suggesting a more uncertain environment.
Options Market Signals:
- IV Rank: 22.5% (Low)
- Current IV: 137.5%
- Expected Move: $4.88
- Put/Call Volume Ratio: 32.65 (Bearish sentiment)
Downside Protection: Support levels at the lower Bollinger Band ($20.29) and the 200-day SMA ($20.52).
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: Above average
Institutional Activity: Above-average institutional interest, with a volume flow of 46 calls vs 1,502 puts.
Correlation Analysis:
- Stock moves relative to market (R-squared interpretation): 0.19, indicating a moderate positive correlation.
Relative Valuation:
- Position within trading range: Bullish, suggesting the stock is near its upper end and potentially due for a pullback or consolidation.
Key Levels & Action Items
Critical Price Levels: Support at $20.29 (lower Bollinger Band) and potential resistance at $25.75 (upper Bollinger Band).
Breakout/Breakdown Levels:
- Breakout level: Above the upper Bollinger Band ($25.75)
- Breakdown level: Below the lower Bollinger Band ($20.29)
Time-Sensitive Catalysts: Upcoming FDA decision on June 30 and potential earnings release.
Risk Management: Stop-loss levels at $20.29 (lower Bollinger Band) and position sizing considerations based on market conditions and risk tolerance.
Generated
News
All VRDN news →
First full quarter of Lumvoa sales beat expectations as patient starts accelerated.
Earnings History
14 of 16 under expected move
Avg Expected Move
18.48%
Avg Actual Move
7.79%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-08-15 | Pre-Market | 35.71% | 49.36% | 1.38x | Exceeded |
| 2023-03-08 | Pre-Market | 15.86% | 10.48% | 0.66x | Within |
| 2023-05-09 | Pre-Market | 17.26% | 0.75% | 0.04x | Within |
| 2023-11-13 | Pre-Market | 10.90% | 1.67% | 0.15x | Within |
| 2024-01-19 | Pre-Market | 11.82% | 0.25% | 0.02x | Within |
| 2024-05-08 | Pre-Market | 16.05% | 1.59% | 0.10x | Within |
| 2024-08-08 | After-Close | 20.01% | 0.66% | 0.03x | Within |
| 2024-11-12 | Pre-Market | 7.58% | 12.76% | 1.68x | Exceeded |
| 2025-02-27 | Pre-Market | 23.82% | 1.55% | 0.07x | Within |
| 2025-05-06 | Pre-Market | 23.63% | 8.31% | 0.35x | Within |
| 2025-08-06 | After-Close | 12.50% | 3.90% | 0.31x | Within |
| 2025-11-05 | Pre-Market | 21.73% | 8.29% | 0.38x | Within |
| 2026-02-26 | Pre-Market | 29.28% | 1.90% | 0.06x | Within |
| 2026-05-05 | After-Close | 11.33% | 6.51% | 0.57x | Within |
| 2026-08-05 | Pre-Market | 18.47% | 1.10% | 0.06x | Within |
| 2026-11-04 | Pre-Market | 19.68% | 15.53% | 0.79x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VRDN Options Activity & IV Rank
VRDN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 69.4%
7-DTE IV: 101.6%
Expected Move: $4.95
7-DTE Move: $4.20
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,723
Put Volume: 778
P/C Volume: 0.452
BULLISH
Call OI: 3,039
Put OI: 971
P/C OI: 0.32
Total OI: 4,010
ATM Options Pricing
ATM Call: $2.45
ATM Put: $2.50
Call %: 8.2%
Put %: 8.4%
Chain Summary
Chain Volume: 2,501
Chain OI: 4,010
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 100th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
100%
vs own history
GEX tilt
+0.98
OI-weighted, today
Vanna tilt
-0.73
δ-sensitivity to IV
Charm tilt
+0.78
δ-decay vs time
Vanna tilt -0.73: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.78: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)23.2LowNov 9
IV Rank (30 DTE)13.4LowNov 9
Straddle Price (30 DTE)$4.95Nov 9
Beta Analysis
Risk Metrics
Beta: 1.1268
Alpha: 21.13%
Correlation: 0.2157
R-Squared: 4.7%
Stock Volatility: 71.8%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own VRDN
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $43.0M | #369 of 1945 | +625.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $32.7M | #887 of 6285 | +1185.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $14.1M | #876 of 3138 | +278.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.4M | #2476 of 3716 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $6K | #4202 of 4729 | -81.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VRDN Institutional Ownership (13F)
Filings for 2026-06-30 · 70 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 104,544,042 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$8.00M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $2.56M | 31.96% | 2026-06-30 |
| 2 | NOMURA HOLDINGS INC | $1.84M | 23.02% | 2026-06-30 |
| 3 | J. Goldman & Co LP | $1.24M | 15.51% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $856.04K | 10.71% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $551.10K | 6.89% | 2026-06-30 |
| 6 | Greenland Capital Management LP | $459.25K | 5.74% | 2026-06-30 |
| 7 | Point72 Asset Management, L.P. | $238.81K | 2.99% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $170.84K | 2.14% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $84.42K | 1.06% | 2026-09-30 |
4 filers$1.73M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $911.15K | 52.61% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $573.14K | 33.09% | 2026-06-30 |
| 3 | Greenland Capital Management LP | $183.70K | 10.61% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $63.83K | 3.69% | 2026-09-30 |
VRDN Insider Trading (Form 4)
Latest: 2026-08-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Jennifer Tousignant | Chief Legal Officer | Mixed Sell −14,212 · Exer +10,000 |
−4,212 | $20.33 | -$204.1K | EDGAR |
| 2026-08-18 | Radhika Tripuraneni | Chief Medical Officer | Exer (M) | +40,000 | $13.21 | $528.4K | EDGAR |
| 2026-07-02 | Arlene Morris | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-07-02 | Jeffrey Robert Ajer | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-07-02 | Christopher W. Cain | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-07-02 | Sarah Gheuens | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-07-02 | Tomas Kiselak | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-07-02 | Jennifer K. Moses | Director | Grant (A) | +32,341 opt | — | EDGAR | |
| 2026-05-13 | Fairmount Funds Management LLC | Director | Buy (P) | +1,176,470 | $17.00 | $20.00M | EDGAR |
| 2026-03-09 | Stephen F. Mahoney | President and CEO | Tax (F) | −7,408 | $30.19 | -$223.6K | EDGAR |
| 2026-03-09 | Seth Harmon | Chief Financial Officer | Tax (F) | −2,031 | $30.19 | -$61.3K | EDGAR |
| 2026-03-09 | Thomas W. Beetham | Chief Operating Officer | Tax (F) | −3,048 | $30.19 | -$92.0K | EDGAR |
| 2026-03-09 | Jennifer Tousignant | Chief Legal Officer | Tax (F) | −1,675 | $30.19 | -$50.6K | EDGAR |
| 2026-03-04 | Seth Harmon | Chief Financial Officer | — | — | — | EDGAR | |
| 2026-03-04 | Stephen F. Mahoney | President and CEO | Mixed Tax −7,627 · Exer +18,357 |
+10,730 | $29.32 | -$223.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VRDN Insider Holdings
5 insiders · @ $29.83
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Director | 5,090,928 | $151.86M | $80.00M | 6 | 2026-05-13 |
| 2 | Radhika Tripuraneni | Chief Medical Officer | 40,000 | $1.19M | $0 | 3 | 2026-08-18 |
| 3 | Stephen F. Mahoney | President and CEO | 33,349 | $994.8K | $499.3K | 5 | 2026-03-09 |
| 4 | Thomas W. Beetham | Chief Operating Officer | 13,361 | $398.6K | $117.0K | 5 | 2026-03-09 |
| 5 | Seth Harmon | Chief Financial Officer | 7,850 | $234.2K | $0 | 5 | 2026-03-09 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VRDN Board & Officers
As of SEC filings through Aug 20, 2026Directors 10
- Arlene Morris · since Jan 3, 2018
- Tomas Kiselak · since Oct 27, 2020
- Jennifer K. Moses · since Jul 14, 2021
- Fairmount Funds Management LLC (entity) · listed since Sep 2021
- Fairmount Healthcare Fund II GP LLC (entity) · listed since Aug 2022
- Fairmount Healthcare Fund II L.P. (entity) · listed since Aug 2022
- Sarah Gheuens · since Sep 21, 2023
- Stephen F. Mahoney · since Oct 30, 2023
- Christopher W. Cain · since Mar 10, 2025
- Jeffrey Robert Ajer · since Apr 7, 2025
Officers 5
- Stephen F. Mahoney · President and CEO · since Oct 30, 2023
- Seth Harmon · Chief Financial Officer · listed since Mar 2025
- Thomas W. Beetham · Chief Operating Officer · since Oct 30, 2023
- Jennifer Tousignant · Chief Legal Officer · since Feb 12, 2024
- Radhika Tripuraneni · Chief Medical Officer · since Mar 10, 2025
10% owners 3
- Fairmount Funds Management LLC (entity) · listed since Sep 2021
- Fairmount Healthcare Fund II GP LLC (entity) · listed since Aug 2022
- Fairmount Healthcare Fund II L.P. (entity) · listed since Aug 2022
Changes in the last 10 years (85)
| Apr 7, 2025 | Jeffrey Robert Ajer became a director |
| Mar 10, 2025 | Radhika Tripuraneni became Chief Medical Officer |
| Mar 10, 2025 | Christopher W. Cain became a director |
| Mar 5, 2025 | The company announced the departure of Peter Evan Harwin from the board in an SEC filing |
| Mar 4, 2025 | Seth Harmon listed as Chief Financial Officer (previously Senior Vice President of Finance) in SEC filings |
| Feb 12, 2024 | Jennifer Tousignant became Chief Legal Officer |
| Jan 3, 2024 | Thomas Ciulla became Chief Medical Officer |
| Jan 3, 2024 | The company announced the departure of Barrett Katz as Chief Medical Officer in an SEC filing |
| Nov 1, 2023 | Fairmount Healthcare Fund L.P. no longer listed as a 10% owner in SEC filings |
| Nov 1, 2023 | Fairmount Healthcare Fund GP LLC no longer listed as a 10% owner in SEC filings |
| Oct 30, 2023 | Thomas W. Beetham became Chief Operating Officer |
| Oct 30, 2023 | Stephen F. Mahoney became a director |
| Oct 30, 2023 | Stephen F. Mahoney became President and CEO |
| Oct 29, 2023 | The company announced the departure of Scott Dunseth Myers from the board in an SEC filing |
| Oct 29, 2023 | The company announced the departure of Scott Dunseth Myers as Chief Executive Officer in an SEC filing |
| Sep 21, 2023 | Sarah Gheuens became a director |
| Sep 12, 2023 | Seth Harmon became Senior Vice President of Finance |
| Sep 8, 2023 | The company announced the departure of Kristian Humer as CFO and CBO in an SEC filing |
| Jun 6, 2023 | Lara Meisner listed as Chief Legal Officer (previously General Counsel and Secretary) in SEC filings |
| Apr 12, 2023 | The company announced the departure of Carrie Melvin as COO in an SEC filing |
| Feb 7, 2023 | Jonathan Violin reported in an SEC filing no longer being a director |
| Feb 7, 2023 | Jonathan Violin reported in an SEC filing no longer being Chief Executive Officer |
| Feb 6, 2023 | Scott Dunseth Myers became a director |
| Feb 6, 2023 | Scott Dunseth Myers became Chief Executive Officer |
| Aug 19, 2022 | Fairmount Healthcare Fund L.P. first listed as a director in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund L.P. first listed as a 10% owner in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund II L.P. first listed as a director in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund II L.P. first listed as a 10% owner in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund II GP LLC first listed as a director in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund II GP LLC first listed as a 10% owner in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund GP LLC first listed as a director in an SEC filing |
| Aug 19, 2022 | Fairmount Healthcare Fund GP LLC first listed as a 10% owner in an SEC filing |
| Jun 21, 2022 | Carrie Melvin became COO |
| Feb 3, 2022 | Jonathan Violin listed as Chief Executive Officer (previously President and COO) in SEC filings |
| Oct 1, 2021 | Lara Meisner became General Counsel and Secretary |
| Sep 28, 2021 | Frazier Life Sciences Public Fund, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 28, 2021 | Fhmlsp, L.p. reported in an SEC filing no longer being a 10% owner |
| Sep 28, 2021 | Fhmlsp, L.l.c. reported in an SEC filing no longer being a 10% owner |
| Sep 23, 2021 | Fairmount Funds Management LLC first listed as a director in an SEC filing |
| Sep 23, 2021 | Fairmount Funds Management LLC first listed as a 10% owner in an SEC filing |
| Aug 16, 2021 | Frazier Life Sciences Public Fund, L.P. became a 10% owner |
| Aug 16, 2021 | Fhmlsp, L.p. became a 10% owner |
| Aug 16, 2021 | Fhmlsp, L.l.c. became a 10% owner |
| Jul 26, 2021 | Kristian Humer became CFO and CBO |
| Jul 14, 2021 | Jennifer K. Moses became a director |
| Jan 20, 2021 | Jonathan Violin first listed as a director in an SEC filing |
| Jan 20, 2021 | Barrett Katz became Chief Medical Officer |
| Jan 15, 2021 | Lee M. Rauch left the board, per their own SEC filing |
| Jan 15, 2021 | Lee M. Rauch left as President & CEO, per their own SEC filing |
| Jan 15, 2021 | Diana Escolar left as Chief Medical Officer, per their own SEC filing |
| Dec 7, 2020 | Rajeev M. Shah became a 10% owner |
| Dec 7, 2020 | Ra Capital Management, L.p. became a 10% owner |
| Dec 7, 2020 | RA Capital Healthcare Fund LP became a 10% owner |
| Dec 7, 2020 | Peter Kolchinsky became a 10% owner |
| Nov 10, 2020 | Point72 Capital Advisors, Inc. became a 10% owner |
| Nov 10, 2020 | Point72 Asset Management, L.P. became a 10% owner |
| Nov 10, 2020 | Cohen Steven A/sac Capital Mgmt LP became a 10% owner |
| Nov 4, 2020 | Logos Global Master Fund LP became a 10% owner |
| Oct 27, 2020 | Tomas Kiselak became a director |
| Oct 27, 2020 | Peter Evan Harwin became a director |
| Oct 27, 2020 | Jonathan Violin became President and COO |
| Oct 15, 2020 | William Stuart Marshall left the board, per their own SEC filing |
| Oct 15, 2020 | William Stuart Marshall left as President & CEO, per their own SEC filing |
| Sep 15, 2020 | Lee M. Rauch listed as President & CEO (previously Chief Operating Officer) in SEC filings |
| Sep 15, 2020 | Lee M. Rauch first listed as a director in an SEC filing |
| Jun 24, 2020 | Lee M. Rauch became Chief Operating Officer |
| Dec 10, 2019 | Diana Escolar became Chief Medical Officer |
| Jan 3, 2018 | Arlene Morris became a director |
| Aug 10, 2017 | Jeffrey S. Hatfield became a director |
| Aug 10, 2017 | Christopher Bowden became a director |
| Feb 13, 2017 | William Stuart Marshall became a director |
| Feb 13, 2017 | William Stuart Marshall became President & CEO |
| Feb 13, 2017 | Thomas E. Hughes became a director |
| Feb 13, 2017 | Remeditex Ventures LLC became a 10% owner |
| Feb 13, 2017 | Paul D Rubin became EVP, Research & Development |
| Feb 13, 2017 | Kyle Lefkoff became a director |
| Feb 13, 2017 | Kevin Koch became a director |
| Feb 13, 2017 | Joseph L Turner became a director |
| Feb 13, 2017 | John W Creecy became a director |
| Feb 13, 2017 | Jason A. Leverone became CFO, Treasurer & Secretary |
| Feb 13, 2017 | Bruce Booth became a director |
| Feb 13, 2017 | Bennett S Lebow reported in an SEC filing no longer being a director |
| Feb 13, 2017 | Bennett S Lebow reported in an SEC filing no longer being a 10% owner |
| Feb 13, 2017 | Atlas Venture Fund VII L P became a 10% owner |
| Feb 13, 2017 | Adam Scott Levy became Chief Business Officer |
Not reported recently (27)
- Fairmount Healthcare Fund GP LLC · Last reported as a director in an SEC filing dated Apr 1, 2024
- Fairmount Healthcare Fund L.P. · Last reported as a director in an SEC filing dated Apr 1, 2024
- Thomas Ciulla · Last reported as Chief Medical Officer in an SEC filing dated Feb 7, 2024
- Lara Meisner · Last reported as Chief Legal Officer in an SEC filing dated Jun 20, 2023
- Joseph L Turner · Last reported as a director in an SEC filing dated Feb 8, 2021
- Jeffrey S. Hatfield · Last reported as a director in an SEC filing dated Feb 8, 2021
- Jason A. Leverone · Last reported as CFO, Treasurer & Secretary in an SEC filing dated Jan 20, 2021
- Peter Kolchinsky · Last reported as a 10% owner in an SEC filing dated Dec 17, 2020
- RA Capital Healthcare Fund LP · Last reported as a 10% owner in an SEC filing dated Dec 17, 2020
- Ra Capital Management, L.p. · Last reported as a 10% owner in an SEC filing dated Dec 17, 2020
- Rajeev M. Shah · Last reported as a 10% owner in an SEC filing dated Dec 17, 2020
- Point72 Asset Management, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 20, 2020
- Cohen Steven A/sac Capital Mgmt LP · Last reported as a 10% owner in an SEC filing dated Nov 20, 2020
- Point72 Capital Advisors, Inc. · Last reported as a 10% owner in an SEC filing dated Nov 20, 2020
- Logos Global Master Fund LP · Last reported as a 10% owner in an SEC filing dated Nov 16, 2020
- Kevin Koch · Last reported as a director in an SEC filing dated May 22, 2020
- Thomas E. Hughes · Last reported as a director in an SEC filing dated May 22, 2020
- Christopher Bowden · Last reported as a director in an SEC filing dated May 22, 2020
- Paul D Rubin · Last reported as EVP, Research & Development in an SEC filing dated Feb 8, 2019
- Adam Scott Levy · Last reported as Chief Business Officer in an SEC filing dated Feb 8, 2019
- Bruce Booth · Last reported as a director in an SEC filing dated Jun 28, 2018
- Kyle Lefkoff · Last reported as a director in an SEC filing dated Jun 30, 2017
- John W Creecy · Last reported as a director in an SEC filing dated Jun 30, 2017
- Remeditex Ventures LLC · Last reported as a 10% owner in an SEC filing dated Feb 13, 2017
- Atlas Venture Fund VII L P · Last reported as a 10% owner in an SEC filing dated Feb 13, 2017
- David A Gonyer · Last reported as a director in an SEC filing dated Feb 8, 2017
- Robin L Smith · Last reported as a director in an SEC filing dated Feb 7, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VRDN Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $348K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Tousignant Jennifer (1, $348K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | Officer | 14,212 | $348.2K | 2026-08-19 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-04 | Beetham Thomas W. | Officer | 3,048 | $92.0K | 2026-03-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-04 | Tousignant Jennifer | Officer | 1,675 | $50.6K | 2026-03-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-04 | Harmon Seth | Officer | 2,031 | $61.3K | 2026-03-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-04 | Mahoney Stephen F. | Officer, Director | 7,408 | $223.6K | 2026-03-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-31 | Tousignant Jennifer | Officer | 2,272 | $70.8K | 2025-12-31 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-12-18 | Meisner Lara | Former Officer | 9,375 | $198.4K | 2023-12-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-12-12 | Humer Kristian | Former CFO | 252,600 | $4.33M | 2023-12-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-12-07 | Humer Kristian | Former Officer | 24,900 | $470.9K | 2023-12-07 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-12-01 | Meisner Lara | Former Officer | 3,125 | $53.0K | 2023-12-01 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
66 ETFs hold VRDN
25 shown · $379.62M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.10% | $74.3M | $76.6B | 2026-11-06 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.74% | $73.7M | $10.0B | 2026-11-05 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $69.3M | — | 2026-09-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $26.4M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.17% | $24.2M | $13.9B | 2026-11-06 |
| 6 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.06% | $20.0M | — | 2026-11-05 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $12.0M | — | 2026-09-30 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.9M | — | 2026-08-31 |
| 9 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $8.9M | — | 2026-11-05 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.73% | $8.7M | $1.2B | 2026-11-06 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.10% | $7.5M | — | 2026-11-05 |
| 12 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.54% | $7.0M | $1.3B | 2026-11-06 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.9M | — | 2026-09-30 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $4.5M | $93.2B | 2026-11-06 |
| 15 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.12% | $3.3M | — | 2026-06-30 |
| 16 | LFSC F/m Emerald Life Sciences Innovation ETF | Nport | 2.53% | $3.2M | — | 2026-08-31 |
| 17 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.31% | $3.2M | — | 2026-08-31 |
| 18 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.8M | $13.7B | 2026-11-06 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.51% | $2.7M | — | 2026-11-06 |
| 20 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $2.6M | — | 2026-11-05 |
| 21 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.17% | $2.3M | $1.4B | 2026-11-06 |
| 22 | ILDR First Trust Innovation Leaders ETF | First Trust | 0.70% | $2.2M | $316.1M | 2026-11-06 |
| 23 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.08% | $2.0M | $2.7B | 2026-11-06 |
| 24 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.13% | $1.7M | — | 2026-09-30 |
| 25 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.4M | — | 2026-08-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.83
TTM Revenue
$26.31M
TTM Net Income
$-397.37M
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $25.75M | $-91.44M | $-0.81 | — |
| Q2 '26 | 2026-06-30 | $284.00K | $-112.82M | $-1.05 | $-105.32M |
| Q1 '26 | 2026-03-31 | $141.00K | $-92.03M | $-0.90 | $-119.65M |
| Q4 '25 | 2025-12-31 | $132.00K | $-101.07M | $-1.10 | $-23.75M |
| Q3 '25 | 2025-09-30 | $70.57M | $-28.17M | $-0.34 | $-84.61M |
| Q2 '25 | 2025-06-30 | $75.00K | $-81.98M | $-1.00 | $-75.37M |
| Q1 '25 | 2025-03-31 | $72.00K | $-70.69M | $-0.87 | $-92.65M |
| Q4 '24 | 2024-12-31 | $72.00K | $-64.46M | $-0.81 | $-73.33M |
| Q3 '24 | 2024-09-30 | $86.00K | $-58.76M | $-0.88 | $-67.71M |
| Q2 '24 | 2024-06-30 | $72.00K | $-49.45M | $-0.77 | $-46.06M |
| Q1 '24 | 2024-03-31 | $72.00K | $-36.15M | $-0.59 | $-45.22M |
| Q4 '23 | 2023-12-31 | $72.00K | $-4.13M | $0.06 | $-38.00M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.24
P/S
39.51
EV/EBITDA
—
EV/Sales
42.20
ROE
-50.5%
ROA
-30.4%
Div Yield
0.00%
FCF Yield
-11.86%
Debt/Equity
0.54
Current Ratio
—
Market Cap
$2.81B
as of 2026-11-09
VRDN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +56.9% | 25 |
| SYRE Spyre Therapeutics, Inc. Common Stock | $9.9B | — | — | +256.7% | 11 |
| CORT Corcept Therapeutics Inc. | $7.9B | 59.3 | +30.0% | +97.0% | 100 |
| MIRM Mirum Pharmaceuticals, Inc. Common Stock | $6.1B | — | +42.2% | +18.2% | 35 |
| COGT Cogent Biosciences, Inc. Common Stock | $5.5B | — | — | −3.5% | 94 |
| BLLN BillionToOne, Inc. Class A Common Stock | $5.4B | 164.1 | — | +28.7% | 47 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $4.8B | — | −60.8% | +127.6% | 79 |
| TVTX Travere Therapeutics, Inc. Common Stock | $4.8B | — | +49.4% | +28.5% | 22 |
| VRDN Viridian Therapeutics, Inc. Common Stock | $3.2B | — | −62.8% | −2.8% | 13 |
| Peer median | $5.8B | 111.7 | +42.2% | +42.8% | 41 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
18.00M
SI % of Float
18.48%
Days to Cover
8.02
Short Vol Ratio
26.5%
Free Float
97.43M
Float %
86.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-20